Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine H1 Revenues Rise Sharply as it Awaits IPO

NEW YORK (GenomeWeb News) – Foundation Medicine's revenues through the first half of 2013 increased 363 percent year over year, the company said in its amended Form S-1 on Friday.

The Cambridge, Mass.-based firm, which filed to go public almost three weeks ago, said that revenues through June 30 rose to $11.1 million, compared to $2.4 million during the year-ago period. Net loss for the six months increased to $17.4 million from $11.3 million a year ago.

R&D spending spiked 68 percent year over year to $11.1 million from $6.6 million, while SG&A costs more than doubled to $12.6 million from $5.0 million.

Foundation said that it had $36.0 million in cash and cash equivalents and $32.2 million in working capital as of June 30.

The company said in its Form S-1 that it plans to raise as much as $86.3 million in its initial public offering, but has not said how many shares it anticipates offering or priced its shares. It plans to list on the Nasdaq under ticker symbol "FMI".

Goldman Sachs and JP Morgan Securities are the joint book-running managers on the offering. Leerink Swann and Sanford Bernstein are also named as underwriters.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.